Patent landscape and claim-scope analysis for US Patent 12,390,398 (medical container connector with deflection element protecting pinch-off)
US 12,390,398 protects a specific medical container/connector architecture: a connector element with a pinch-off section and a head section having a “locking rim” plus an “another rim” that radially extends beyond it, where a deflection element extends from the another rim toward the first end and terminates inside the lumen portion of the pinch-off section to protect the pinch-off without blocking pinching. The estate is claim-structured to cover both the container itself and the resulting filled pharmaceutical product, with additional dependent claim hooks for closure/membrane sealing, deflection geometry, and flexible-foil chambers.
A competitive risk for generics and biosimilars is low because this is device/container IP, not an active ingredient patent. The competitive risk is instead with infusion/administration sets, unit-dose parenteral feeding bags, spike ports, and multi-chamber containers that use similar “pinch-off” and locking-closure mechanics, particularly where a protective internal deflection feature is used near the pinch-off region.
What does US 12,390,398 claim protect?
Core protected concept (independent claim 1):
A medical container includes:
- A chamber with a medical fluid
- A connector secured to the chamber, where the connector has:
- A connector element with inner lumen
- A fastening section at the first end secured to the chamber
- A pinch-off section extending from the fastening section toward the second end
- A head section extending from the pinch-off section toward the second end
- The head section comprises:
- A locking rim
- Another rim extending radially beyond the locking rim, positioned closer to the first end
- A deflection element directly connected to and extending from the another rim toward the first end
- The deflection element ends with a portion that extends into the lumen area defined by the pinch-off section to protect the pinch-off section without hindering pinching
Interpretation posture for claim scope (what matters most for infringement):
- The “deflection element” must be connected to the “another rim” and oriented toward the fastening side (first end).
- The deflection element’s end must extend into the inner lumen portion associated with the pinch-off section.
- The “without hindering pinching” limitation constrains functional relationship: the deflection feature must be positioned such that it protects the pinch-off section but still allows pinch-off actuation.
Where the claim is tight (high design constraints):
- Two-rim geometry: “locking rim” plus “another rim radially beyond” it, with relative axial position (another rim closer to first end).
- Deflection element placement/termination: within the lumen portion near pinch-off, and connected specifically to the another rim.
Where the claim is broader (less constrained):
- The chamber content is broadly “medical fluid” in claim 1; later claims narrow to parenteral feeding.
- The fastening section is open-ended in claim 1 (dependent claims address welding or insertion between flexible foils).
How broad are claims 1 and 9 compared to dependent claims 2–8 and 10–21?
Independent claim 1 vs independent claim 9
- Claim 1: medical container definition.
- Claim 9: pharmaceutical product definition that includes the same connector structure.
Practical scope implication:
Any accused system that contains the connector architecture in a container will likely map to claim 1. If the system also qualifies as a “pharmaceutical product” in the commercial sense (filled with a pharmaceutical-grade medical fluid for treatment), claim 9 becomes the cleanest path.
Dependent claims that add incremental infringement hooks
Key dependent limitations:
- Claim 2 / Claim 10: closure element locks to the locking rim and axially terminates at the another rim.
- Claim 3 / Claim 11: membrane element between connector element and closure seals lumen.
- Claim 4 / Claim 12: deflection element is radially spaced from and within a wall of the pinch-off section.
- Claim 5 / Claim 13: deflection element does not axially overlap with the head section.
- Claim 6 / Claim 14: chamber made from multiple flexible foils; fastening section inserted between two foils.
- Claim 7 / Claim 15: fastening section welded to chamber.
- Claim 8 / Claim 16: medical fluid is parenteral feeding.
- Claim 17 / Claim 16 + 17: fluid includes glucose, fat, amino acid solutions.
- Claims 18–21: repeat closure/membrane/deflection geometry constraints in the parenteral feeding context.
Scope mapping risk:
- If a competitor uses the same two-rim head geometry and lumen-terminating internal deflection but uses a different closure approach, claim 1 can still be in play (closure/membrane are only in dependent claims).
- If a competitor omits the functional “protect without hindering pinching” geometry, they can avoid claims 1/9 but must redesign the pinch-off protective feature.
What patent claim elements are most likely to be asserted in litigation (and hardest to design around)?
Most likely litigated limitations
- Two-rim head geometry
- locking rim + another rim radially beyond, with axial ordering (another rim closer to first end)
- Deflection element connected to another rim
- direct connection is explicit
- Deflection terminus into lumen portion defined by pinch-off section
- termination inside the pinch-off lumen portion is explicit
- Functional constraint: protect pinch-off without hindering pinching
- reduces permissive interpretation of placement/size
Design-around opportunities (high-level)
- Move the protective feature so it no longer terminates into the pinch-off lumen portion.
- Replace the connected internal deflection with an external guard that does not interface the lumen portion used for pinching.
- Eliminate the “another rim radially beyond locking rim” configuration or change the axial ordering relative to first end so the claim’s rim topology is not met.
These are design changes; whether they avoid literal and/or doctrine-of-equivalents arguments depends on claim construction and prosecution history, which is not provided here.
Do claims cover single- and multi-chamber medical containers? (claims 22–24)
Independent claim 22 expands coverage to a medical container with:
- First chamber + first connector
- Second chamber + second connector
- Each connector uses the same connector element architecture with the two-rim head and internal deflection protecting the pinch-off
Dependent claim 23 adds that the two medical fluids are different.
Dependent claim 24 adds parenteral feeding composition categories to both chambers.
Competitive landscape implication:
This is relevant to multi-chamber infusion bags and sequencing devices where two or more fluids are delivered through different channels or connected ports, each using a pinch-off connector system with the protective deflection feature.
What formulations and therapeutic use are explicitly covered? (parenteral feeding)
- Claim 8 / Claim 16: “fluid for parenteral feeding of a patient”
- Claim 17: includes glucose solution, fat solution, amino acid solution
Scope note:
The patent is not limited to one parenteral nutrition composition. It is limited by the claim text to those types of fluids when relying on dependent claim 17. Claim 1/9 remain broader for “medical fluid” even if parenteral feeding is not the marketing category.
What Orange Book status would apply to US 12,390,398?
No “Orange Book status” applies in the usual active pharmaceutical ingredient sense because this is a device/container patent tied to a medical container connector structure. US FDA’s Orange Book is for approved drug products and therapeutic equivalents, not container device patents. If the device is sold/used with a listed drug product, it may still appear in patent listings only if the relevant NDA/BLA is tied to the product and the patent is listed for that specific drug application, which cannot be determined from the claim text alone.
What other patents are likely in the same landscape (adjacent technology clusters)?
Even without identifying citations from the record, US 12,390,398’s claim language clusters around:
- Infusion bag connector ports with pinch-off sections (thermal/mechanical pinch actuation)
- Locking rim / closure snap-lock or thread-lock mechanics with a lumen-sealing membrane
- Protective internal features to prevent damage/leaks at pinch-off
- Multi-foil flexible chambers where the fastening section is inserted/welded
- Multi-chamber container manifolds where each connector follows the same port architecture
In infringement analysis, you typically triangulate around:
- Prior art connectors with pinch-off features
- Later design improvements that add internal deflection/protection to reduce pinch-off failure modes
- Closure systems that interface with a two-rim head geometry
- Sealing membranes used in spike-less or connector-locked fluid paths
Those adjacent patents matter because they define likely prosecution boundaries and the breadth of “protect without hindering pinching.”
How strong is the patent estate for the key differentiating element (deflection protecting pinch-off)?
Strength drivers (intrinsic to the claim set you provided):
- The claim ties protection to a specific structural-to-functional relationship (deflection into pinch-off lumen portion; protects without hindering pinching).
- The claim anchors the deflection element to the “another rim” (not just “a deflection element anywhere”).
- Dependent claims add geometry constraints (radial spacing within wall; no axial overlap with head).
Strength limits:
- If a competitor uses an equivalent protective geometry but relocates connection points or alters rim topology, they may argue non-infringement.
- If the patent was drafted to overcome specific prior art, the prosecution history could tighten interpretations around “another rim” and the deflection termination.
The overall posture is medium-to-strong on the specific architecture, weaker against broad “any pinch-off connector with protection” arguments.
What generic entry risks exist for this patent?
None in the standard “generic drug” sense. The competitive threat is:
- Substitute connector designs that avoid the claim’s structural requirements
- Licensing of the connector technology
- Re-engineering pinch-off protection mechanisms
If the protected container is used as part of a drug product delivery system, a drug sponsor can mitigate risk by:
- Switching to alternative container platforms
- Sourcing from different manufacturers with different connector geometry
- Negotiating a license for container components
Which companies are likely competing with this connector architecture?
Company identification requires the patent assignee, inventor list, and prosecution/citations record, none of which are included in the input. Without that, naming challengers would be speculative.
What would a “pinch-off connector with internal deflection” design look like to avoid infringement?
A non-infringing direction typically changes at least one mandatory element:
- Remove the two-rim head structure as claimed (no “another rim radially beyond locking rim” with the required axial ordering).
- Connect the deflection element to a different rim portion or to the pinch-off wall rather than “directly connected to and extending from the another rim.”
- Ensure the deflection element does not terminate into the lumen portion defined by the pinch-off section.
- Use an external shield that protects the pinch region but does not extend into the pinching lumen zone that interacts with the pinch-off.
Whether equivalents arguments succeed depends on claim construction, which cannot be assessed from the claim text alone.
Timeline and exclusivity (what dates matter)
Exclusivity timeline depends on:
- Patenting dates (filing date, priority date)
- Whether patent term adjustment or disclaimers apply
- Whether the patent is listed for an NDA/BLA (device/container patent listing can affect regulatory exclusivity strategies)
Those dates are not provided in the input. A complete exclusivity timeline cannot be generated from claim text.
Key Takeaways
- US 12,390,398 protects a medical container connector with a pinched-off lumen and a head section defined by two rims (locking rim plus radially beyond “another rim”), coupled to an internal deflection element terminating into the pinch-off lumen portion to protect the pinch-off without hindering pinching.
- Claim coverage is robust for systems that use the same two-rim/deflection topology, even without requiring closure locking or membranes (those are dependent).
- Dependent claims narrow to closure/membrane sealing, specific deflection geometry (radial spacing within pinch-off wall; no axial overlap with head), and fastening methods (inserted between flexible foils, or welded).
- The pharmaceutical-product claims explicitly cover parenteral feeding fluids, including glucose, fat, and amino acid solutions, but the core connector claim remains broader for other medical fluids.
- Competitive risk is design-and-licensing focused, not generic-drug “entry” driven.
FAQs
1) What is the single most important feature for infringement of US 12,390,398?
The deflection element connected to the “another rim” and terminating into the inner lumen portion defined by the pinch-off section to protect the pinch-off without hindering pinching.
2) Do the claims require a closure element?
No. Closure is required only in dependent claims (2/10 and related dependents). Independent claims 1 and 9 cover the container and connector structure without requiring closure.
3) Are multi-chamber containers covered?
Yes. Claim 22 covers first and second chambers with first and second connectors using the same connector element architecture.
4) Is the patent limited to parenteral nutrition?
Dependent claim 17 narrows fluid composition categories. Independent claims 1 and 9 cover “medical fluid” more generally.
5) Does the patent protect drug ingredients or only the delivery container?
Based on the provided claims, it protects the medical container/connector structure and the resulting pharmaceutical product as defined by the container and connector, not an active ingredient.
References
(No external sources were provided or identifiable from the input; no patent bibliographic record, assignee, file history, or FDA/Orange Book listing details were included in the prompt.)
